Evidence map›Paper›PMID 35751573›Full record

ArticleNeuro-oncology2022

Preclinical modeling in leptomeningeal disease: Starting at the foundation to tackle a difficult disease.

Priya Kumthekar, Seema Nagpal

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Priya KumthekarDepartment of Neurology at The Feinberg School of Medicine at Northwestern University and The Malnati Brain Tumor Institute at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.ORCID 0000-0001-5923-0677
Seema NagpalDepartment of Neurology at Stanford University, Department of Neurology, Division of Neuro-oncology, Stanford, California, USA.ORCID 0000-0002-0289-2319

Funding

STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Atique U. Ahmed · 2018 to 2026
$21.4M
NCI NIH HHS P50 CA221747
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MelanomaMeningeal NeoplasmsNeoplastic Cells, CirculatingHumans

Identifiers

PMID35751573
PMCPMC9527512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.